Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
- PARP Inhibitors May Be Effective in Brain, Other Cancers with IDH Mutations
Studies presented at the 2017 AACR annual meeting suggest that therapies which take advantage of the mutations in the IDH gene may be more effective than drugs that block it.
- Making Greater Progress Against Cancer—Not Just a Hope but a Reality
Acting NCI Director Dr. Doug Lowy discusses what he calls encouraging news in the most recent Annual Report to the Nation and how NCI is helping to achieve further progress against cancer.
- Studies Identify Potential Treatment Strategies for Pediatric DIPG Brain Tumors
Two studies have identified proteins that drive growth of diffuse intrinsic pontine glioma (DIPG) tumor cells. Blocking these targets with investigational drugs slowed tumor growth in animal models.
- FDA Approves Niraparib as Maintenance Therapy for Recurrent Ovarian Cancer
The FDA approved the PARP inhibitor niraparib for use as a maintenance therapy for some women with advanced ovarian cancer.
- FDA Approves Ribociclib, Expands Palbociclib Approval for Metastatic Breast Cancer
The FDA has approved a new targeted therapy, ribociclib, and expanded its earlier approval of another targeted therapy, palbociclib, for some women with metastatic breast cancer.
- Advancing the Potential and Promise of Total-Body PET Imaging
A total-body PET scanner under development is an ideal example of how NCI and NIH are supporting the development of new research and cancer care-related technologies.
- Avelumab Becomes First Approved Treatment for Patients with Merkel Cell Carcinoma
The FDA has approved the first drug ever for the rare skin cancer, Merkel cell carcinoma, and updated data show an improved tumor response rate and that patients’ tumors continued to respond for at least a year.
- Blinatumomab Extends Survival for Patients with Advanced ALL
Patients with previously treated acute lymphoblastic leukemia who received blinatumomab, which encourages the immune system to kill cancer cells, lived longer and experienced fewer side effects than patients given standard chemotherapy.
- Targeted Cancer Drug May Also Help Protect Fertility, Study Suggests
Findings from a new study in mice suggest that a class of targeted cancer drugs may have another use in some younger women being treated for cancer: preserving their fertility.
- Colorectal Cancer Incidence Rising in Young Adults: An Interview with Drs. Philip Rosenberg and William Anderson
Drs. Philip Rosenberg and William Anderson of NCI discuss a recent study on which they were coauthors that reported an increase in colorectal cancer incidence among adults under age 50 in the United States.
- Stem-Cell Based Tool May Help Measure Heart Toxicity of Cancer Drugs
Researchers have used adult stem cells to create a tool for ranking how toxic a group of cancer drugs, called tyrosine kinase inhibitors, are to human heart cells. Such a test could potentially identify toxic side effects earlier in the drug development process.
- Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors
Using a new tool for editing genomes, known as CRISPR, researchers have genetically engineered immune cells and improved the ability of these cells to kill cancer cells in mice.
- FDA Approves New Use for Lenalidomide in Multiple Myeloma
The FDA has approved lenalidomide for use as a maintenance therapy in patients with multiple myeloma who have undergone an autologous stem cell transplant, to help keep the cancer from coming back.
- Putting the Cancer Patient Front and Center: An Interview with NCI’s Dr. Paul Jacobsen
NCI’s Dr. Paul Jacobsen discusses NCI’s Healthcare Delivery Research Program and its role in advancing innovative research to improve the delivery of cancer care.
- Study Shows Platelets Can Deliver Immunotherapy, Reduce Tumor Regrowth
In experiments in mice, researchers show platelets linked to an immunotherapy drug can help eliminate residual cancer cells that remain after surgery. The engineered platelets may also prevent leftover cancer cells from spreading.
- Lung Cancer Screening Pilot Reveals Challenges, Growing Pains
A demonstration project by the Veterans Health Administration is highlighting some of the complexities and challenges associated with the expansion of lung cancer screening in the United States.
- Conditional Reprogramming: An Interview with Dr. Richard Schlegel on Growing Cancer Cells
Dr. Richard Schlegel describes an innovative cell culture technique he helped to develop. Called conditional reprogramming, the technique can be used to rapidly establish cell cultures of normal and tumor cells from patient samples.